These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 20017577)

  • 1. The use of computer models in pharmaceutical safety evaluation.
    Boyer S
    Altern Lab Anim; 2009 Nov; 37(5):467-75. PubMed ID: 20017577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current and Future Perspectives on the Development, Evaluation, and Application of in Silico Approaches for Predicting Toxicity.
    Patlewicz G; Fitzpatrick JM
    Chem Res Toxicol; 2016 Apr; 29(4):438-51. PubMed ID: 26686752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toxicology is IN: in silico, in vitro, integrated testing strategy.
    Caloni F; Benfenati E; Sambuy Y
    ALTEX; 2016; 33(2):187-8. PubMed ID: 27032091
    [No Abstract]   [Full Text] [Related]  

  • 4. Implementing Toxicity Testing in the 21st Century (TT21C): Making safety decisions using toxicity pathways, and progress in a prototype risk assessment.
    Adeleye Y; Andersen M; Clewell R; Davies M; Dent M; Edwards S; Fowler P; Malcomber S; Nicol B; Scott A; Scott S; Sun B; Westmoreland C; White A; Zhang Q; Carmichael PL
    Toxicology; 2015 Jun; 332():102-11. PubMed ID: 24582757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence-Based Toxicology Collaboration (EBTC). Editorial.
    von Aulock S
    ALTEX; 2013; 30(1):1. PubMed ID: 23451363
    [No Abstract]   [Full Text] [Related]  

  • 6. Use of animals for toxicology testing is necessary to ensure patient safety in pharmaceutical development.
    Mangipudy R; Burkhardt J; Kadambi VJ
    Regul Toxicol Pharmacol; 2014 Nov; 70(2):439-41. PubMed ID: 25058855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence-based absorption, distribution, metabolism, excretion (ADME) and its interplay with alternative toxicity methods.
    Tsaioun K; Blaauboer BJ; Hartung T
    ALTEX; 2016; 33(4):343-358. PubMed ID: 27806179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toxicology and stem cells: New frontiers.
    Caloni F; Ferrari M; De Angelis I
    ALTEX; 2014; 31(1):94. PubMed ID: 24448761
    [No Abstract]   [Full Text] [Related]  

  • 9. How omics technologies can contribute to the '3R' principles by introducing new strategies in animal testing.
    Kroeger M
    Trends Biotechnol; 2006 Aug; 24(8):343-6. PubMed ID: 16782220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implementation challenges for designing integrated in vitro testing strategies (ITS) aiming at reducing and replacing animal experimentation.
    De Wever B; Fuchs HW; Gaca M; Krul C; Mikulowski S; Poth A; Roggen EL; Vilà MR
    Toxicol In Vitro; 2012 Apr; 26(3):526-34. PubMed ID: 22269383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The value of in silico chemistry in the safety assessment of chemicals in the consumer goods and pharmaceutical industries.
    Modi S; Hughes M; Garrow A; White A
    Drug Discov Today; 2012 Feb; 17(3-4):135-42. PubMed ID: 22063083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In silico toxicology challenges for pharmaceuticals: complacency or controversy?
    Cronin MT
    Altern Lab Anim; 2009 Nov; 37(5):453-6. PubMed ID: 20017576
    [No Abstract]   [Full Text] [Related]  

  • 13. Predictive toxicology today: the transition from biological knowledge to practicable models.
    Benigni R
    Expert Opin Drug Metab Toxicol; 2016 Sep; 12(9):989-92. PubMed ID: 27351633
    [No Abstract]   [Full Text] [Related]  

  • 14. In silico toxicology for the pharmaceutical sciences.
    Valerio LG
    Toxicol Appl Pharmacol; 2009 Dec; 241(3):356-70. PubMed ID: 19716836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmaceutical toxicology: designing studies to reduce animal use, while maximizing human translation.
    Chapman KL; Holzgrefe H; Black LE; Brown M; Chellman G; Copeman C; Couch J; Creton S; Gehen S; Hoberman A; Kinter LB; Madden S; Mattis C; Stemple HA; Wilson S
    Regul Toxicol Pharmacol; 2013 Jun; 66(1):88-103. PubMed ID: 23524271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reply to: Bayesian network integrated testing strategy and beyond.
    Jaworska J
    ALTEX; 2013; 30(3):391. PubMed ID: 23861082
    [No Abstract]   [Full Text] [Related]  

  • 17. In vitro tests within the REACH information strategies.
    Louekari K; Sihvonen K; Kuittinen M; Sømnes V
    Altern Lab Anim; 2006 Aug; 34(4):377-86. PubMed ID: 16945005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-animal methodologies within biomedical research and toxicity testing.
    Knight A
    ALTEX; 2008; 25(3):213-31. PubMed ID: 18841317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence-based toxicology: strait is the gate, but the road is worth taking.
    Silbergeld E; Scherer RW
    ALTEX; 2013; 30(1):67-73. PubMed ID: 23338807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative in vitro to in vivo extrapolation (QIVIVE): An essential element for in vitro-based risk assessment.
    Yoon M; Blaauboer BJ; Clewell HJ
    Toxicology; 2015 Jun; 332():1-3. PubMed ID: 25680635
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.